Summary Nymox withheld the data that Phase 3 trials of its only drug had failed for 6-12 months after management knew of the failure. During this time, Nymox issued bullish press releases while management continued to aggressively dump stock without timely SEC disclosure. Offshore anonymous Panamanian finance deals; auditor, legal counsel, bankers ALL closely tied…

Read More